Title: LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?
Authors: Egolf, Shaun; Capell, Brian C
Published In Expert Opin Ther Targets, (2020 07)
Abstract: INTRODUCTION: Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer; it can be locally invasive and metastatic. cSCC is an immense clinical and economic problem given its sheer incidence and potential morbidity and mortality, particularly in the elderly and immunocompromised. Epigenetics has emerged as one of the most exciting areas of human biology, impacting virtually all areas of cellular physiology. Inhibition of an epigenetic enzyme is a potential treatment of cSCC. AREAS COVERED: We provide an overview of the development of inhibitors targeting the lysine demethylase, LSD1 (KDM1A), the first histone demethylase discovered. We summarize current treatment modalities for cSCC and provide a rationale for why epigenome-targeting therapies, and particularly LSD1 inhibitors, may be a novel and effective approach for treating pre-malignant and malignant cSCCs. A search was conducted in PubMed utilizing the combination of 'LSD1' with keywords such as 'epidermis,' 'squamous cell carcinoma,' or 'skin.' Relevant papers from 2000 to 2020 were reviewed. EXPERT OPINION: Given the ability of LSD1 inhibitors to promote epidermal differentiation and enhance anti-tumor immune responses, LSD1 inhibitors may offer a highly effective therapeutic approach for the prevention and treatment of these ubiquitous cancers.
PubMed ID: 32379508
MeSH Terms: Aged; Animals; Antineoplastic Agents/pharmacology; Carcinoma, Squamous Cell/drug therapy*; Carcinoma, Squamous Cell/pathology; Drug Development; Epigenesis, Genetic; Histone Demethylases/antagonists & inhibitors*; Histone Demethylases/metabolism; Humans; Molecular Targeted Therapy; Skin Neoplasms/drug therapy*; Skin Neoplasms/pathology